Moderna, Inc.
NASDAQ:MRNABiotechnology
+$2.48 today
- Market cap
- $79.63B
- Beta
- 1.03
- P/E (TTM)
- -7.9
- EPS (TTM)
- -$8.09
Volume 6.91M
Average 6.53M
MRNA Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Moderna, Inc.NASDAQ: MRNA
Net Income · Q3 FY2026 · quarter ended Sep 2026
Net income turns positive
Q3 FY2026 net income was $162M, compared with -$200M a year earlier. Trailing-twelve-month net income was -$2.79B.
Context
- Net income amounted to 145.2% of revenue in FY2025, up 33.8 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 14 analysts of -$2.89B (+2.4%) for the fiscal year ending Dec 2026, a step up from the -20.8% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $162M+120.7% QoQ
- Last fiscal yearDec 2025
- -$2.82B-20.8% YoY
- LTMSep 2026
- -$2.79B-10.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +181.0% | +8.4% | -172.6 pp |
| 1 year | -20.8% | +2.4% | +23.2 pp |
| 3-year CAGR | — | -27.8% | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (2.82B) USD
- Year-over-year change
- +20.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.82B) | +20.8% |
| FY2024 | 2024-12-31 | (3.56B) | +24.5% |
| FY2023 | 2023-12-31 | (4.71B) | -156.4% |
| FY2022 | 2022-12-31 | 8.36B | -31.5% |
| FY2021 | 2021-12-31 | 12.2B | — |
Net Income vs competitors
How MRNA compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -10.5% is the 6th highest of 10, against a peer median of +15.4%.
- Net income amounts to 110.5% of revenue for MRNA, versus a peer median of 64.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | £5.62B GBP | +41.0% | +0.6% | 16.9% | |
| LTM Jun 2026 | $4.37B USD | -59.4% | -37.2% | 6.9% | |
| LTM Sep 2026 | $2.79B USD | -10.5% | — | 110.5% | |
| LTM Jun 2026 | €1.71B EUR | +348.2% | — | 64.7% | |
| LTM Jun 2026 | $1.38B USD | +152.9% | +50.8% | — | |
| LTM Mar 2026 | $442.72M USD | -23.4% | — | 676.0% | |
| LTM Mar 2026 | €146.23M EUR | +81.9% | -7.0% | 93.5% | |
| LTM Mar 2026 | $87.84M USD | -118.3% | — | 14.7% | |
| LTM Mar 2026 | $84.93M USD | -12.0% | -32.8% | — | |
| LTM Mar 2026 | $78.67M USD | +15.4% | — | 173.5% | |
| Peer median (excluding MRNA) | — | +15.4% | -7.0% | 64.7% | |
Competitors are the stored peer set for MRNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 12.2B | 8.36B | (4.71B) | (3.56B) | (2.82B) |
| Depreciation & Amortization | 232M | 348M | 621M | 189M | 215M |
| Deferred Income Tax | (318M) | (559M) | 828M | 0 | 0 |
| Stock-Based Compensation | 142M | 226M | 305M | 429M | 483M |
| Change in Working Capital | 1.31B | (3.46B) | (139M) | (78M) | 254M |
| Accounts Receivables | (1.78B) | 1.79B | 493M | 534M | 156M |
| Inventory | (1.39B) | 492M | 747M | 83M | (34M) |
| Accounts Payables | 204M | 240M | 13M | (69M) | (92M) |
| Other Working Capital | 4.28B | (5.98B) | (1.39B) | (626M) | 224M |
| Other Non-Cash Items | 54M | 59M | (19M) | 17M | (3M) |
| Operating Cash Flow | 13.62B | 4.98B | (3.12B) | (3B) | (1.87B) |
| Capital Expenditures | (284M) | (400M) | (707M) | (1.05B) | (192M) |
| Acquisitions (Net) | 0 | 0 | (85M) | 0 | 0 |
| Purchases of Investments | (12.65B) | (11.44B) | (3.78B) | (6.53B) | (5.77B) |
| Sales of Investments | 4.44B | 6.7B | 8.78B | 9.53B | 7.92B |
| Other Investing Activities | (30M) | (40M) | 0 | 0 | (10M) |
| Investing Cash Flow | (8.52B) | (5.18B) | 4.21B | 1.95B | 1.95B |
| Debt Repayment | (140M) | (184M) | (270M) | (10M) | 539M |
| Common Stock Issued | 124M | 65M | 46M | 66M | 35M |
| Common Stock Repurchased | (857M) | (3.33B) | (1.15B) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 19M |
| Financing Cash Flow | (873M) | (3.45B) | (1.38B) | 56M | 593M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 2M |
| Net Change in Cash | 4.22B | (3.64B) | (289M) | (999M) | 668M |
| Free Cash Flow | 13.34B | 4.58B | (3.83B) | (4.06B) | (2.07B) |
Moderna, Inc.
NASDAQ:MRNA
Intrinsic Alpha fair value
Locked
Current Price
$196.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.